Business Context and Reporting Period
This Form 8-K Current Report was filed by OvaScience, Inc. (noted as Tempest Therapeutics, Inc. in request metadata) on September 6, 2016. The report details significant changes in executive leadership, specifically the appointment of a new Chief Financial Officer and the resignation of the previous CFO.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and employment terms.
- New CFO Base Salary: $400,000 annually.
- Target Bonus: Up to 50% of annual base salary (potential maximum of 150% of target).
- Stock Options: 200,000 shares granted outside the 2012 Stock Incentive Plan.
- Restricted Stock Units (RSUs): 50,000 shares.
- Severance: Six months of base salary and COBRA coverage upon termination without cause or resignation for good reason.
Material Changes
The primary material change reported is the transition of the Chief Financial Officer role:
- Appointment: Christophe Couturier commenced employment as CFO on September 6, 2016. He brings extensive experience from Merck KGaA, including leading the Merck KGaA/Pfizer Global Immuno-Oncology Alliance.
- Resignation: Jeffrey Young resigned as CFO on September 6, 2016, to pursue other opportunities. He agreed to remain for one month to assist with the transition.
Outlook, Risks, and Unusual Items
Compensation Structure and Risks:
- Vesting Acceleration: Stock options and RSUs will accelerate in full in the event of a change of control if Mr. Couturier is terminated without cause or resigns for good reason within one year.
- Performance Grant: An additional grant of up to 75,000 options may be awarded in 2017 subject to performance objectives and Board approval.
- Restrictive Covenants: Mr. Couturier has agreed to non-compete and non-solicitation obligations during his employment and for 12 months following termination.
- Employment Terms: Employment is at-will and may be terminated by either party at any time with or without cause.
Unusual Items: The stock option grant was made outside the Company's existing 2012 Stock Incentive Plan as an inducement material to the acceptance of employment, in accordance with NASDAQ Listing Rule 5635(c)(4).
Investor Verification Checklist
- Verify the exact exercise price of the 200,000 stock options granted to Mr. Couturier, as the filing text states it equals the closing price on the grant date but does not list the specific dollar amount.
- Review the full text of the Offer Letter (Exhibit 10.1) for detailed definitions of "good reason," "change of control," and specific performance objectives.
- Confirm the impact of the CFO transition on the company's ongoing financial reporting and strategic direction.
- Check subsequent filings for the actual vesting schedule execution and any additional option grants in 2017.